Does Anthem (Elevance Health) Cover Rezdiffra (Resmetirom)?

Rezdiffra (resmetirom, made by Madrigal Pharmaceuticals) is an oral thyroid hormone receptor-beta (THR-beta) agonist. It received FDA accelerated approval in March 2024 for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH, formerly called NASH) who have moderate-to-severe liver fibrosis (stages F2 to F3), used alongside diet and exercise. It is not approved for weight loss, simple fatty liver without fibrosis, or cirrhosis.

Anthem (Elevance Health) commercial plans generally do cover Rezdiffra when it is prescribed within that FDA-approved population, but coverage is not automatic. Like other insurers covering a roughly $3,500-per-month specialty drug, Anthem almost certainly requires prior authorization and step therapy documentation before it will pay a claim. The exact prior authorization form, tier placement, coinsurance percentage, and specialist requirement vary by plan, state, and employer group, and none of those specific numbers could be verified against an actual Anthem policy document for this article. Anyone relying on this page to plan a prescription should confirm current PA criteria directly with Anthem member services or the treating specialist's prior-authorization team before assuming a specific dollar amount or turnaround time.

What is established, and what is not

Established (FDA label): Rezdiffra is approved for adults with noncirrhotic MASH and fibrosis stages F2-F3, dosed by body weight, as an adjunct to diet and exercise. This is confirmed on the FDA's drug approval database.

Plausible but plan-specific: It is standard commercial-payer practice, seen across most specialty drugs in this cost range, to require prior authorization, documentation of the diagnosis and fibrosis stage, a trial of a lower-cost first-line therapy (step therapy), and dispensing through a specialty pharmacy. It is reasonable to expect Anthem to follow a similar pattern for Rezdiffra, but this article cannot confirm Anthem's specific criteria word-for-word because no Anthem policy document was available as a source.

Not established from available sources: The exact formulary tier number, the exact coinsurance percentage, the specific specialist-only prescribing rule, the exact lab panel required, and the exact PA turnaround time in business days. These figures appear in some payer coverage summaries circulating online, but they could not be verified here and should not be treated as confirmed Anthem policy. If your plan's PA form differs from what is described below, follow the plan document, not this article.

A safe general statement that holds regardless of plan specifics: Rezdiffra requires prior authorization on essentially all US commercial plans, coverage is limited to the FDA-labeled MASH population with F2-F3 fibrosis, and patients should expect to document a prior attempt at standard-of-care management before approval. The precise percentages, tier numbers, and turnaround windows differ by plan and change over time, so they need direct confirmation with the insurer as of the date you are seeking coverage.

What a prior authorization packet typically needs

Based on how specialty liver-disease drugs are generally reviewed by commercial payers, a PA submission for Rezdiffra is likely to need:

• A confirmed MASH diagnosis, usually from liver biopsy or validated noninvasive testing (FibroScan, MR elastography, or a validated fibrosis score such as FIB-4).
• Documentation that fibrosis is staged F2 or F3, ideally from testing done within roughly the past year.
• Evidence of an attempt at diet and exercise counseling.
• Documentation of a trial of, intolerance to, or contraindication to a recognized first-line pharmacologic option, most commonly vitamin E or pioglitazone in patients without cirrhosis, consistent with the general direction of AASLD's practice guidance on NAFLD/NASH management.
• Baseline labs, including liver enzymes and thyroid function, since resmetirom acts on the thyroid hormone receptor pathway and thyroid status is a clinically relevant baseline measurement.
• Involvement of, or documented consultation with, a gastroenterologist or hepatologist, which many plans favor for specialty liver drugs even when not stated as an absolute rule.

Prescribers should verify the current version of this checklist against Anthem's published medical policy or by calling the plan, since payer PA criteria are revised periodically and the version above reflects general specialty-drug practice rather than a confirmed Anthem document.

Cost and the manufacturer savings program

Rezdiffra's list price is reported at roughly $3,500 per month by the manufacturer and industry trackers, before insurance. Because it sits on a specialty tier, out-of-pocket cost for a commercially insured patient depends heavily on whether the plan uses coinsurance (a percentage of drug cost) or a flat specialty copay, and that split cannot be generalized to a single dollar figure for all Anthem plans.

Madrigal Pharmaceuticals has offered a manufacturer copay savings program for commercially insured patients that can lower out-of-pocket cost, though the current terms, eligibility rules, and annual cap should be checked directly on the manufacturer's site since these programs are updated periodically (verify as of the date you enroll). Copay cards of this type generally cannot be used by patients on Medicare, Medicaid, Tricare, or other government insurance, and coverage for Anthem Medicare Advantage members follows separate Medicare Part D-style rules that differ from commercial PA criteria.

What the clinical trial evidence actually showed

The pivotal trial supporting FDA approval was a large, randomized, placebo-controlled phase 3 study (commonly referred to as MAESTRO-NASH) in adults with biopsy-confirmed NASH and significant fibrosis. It reported that a meaningfully higher proportion of patients on resmetirom achieved NASH resolution without worsening fibrosis, and fibrosis improvement without worsening NASH activity, compared with placebo at roughly one year. It also reported reductions in liver fat on imaging and improvement in LDL cholesterol, consistent with the drug's mechanism as a hepatic THR-beta agonist. The most commonly reported side effects were gastrointestinal, including diarrhea and nausea, typically early in treatment.

The specific percentage point differences between resmetirom and placebo are widely cited in secondary sources, but this article intentionally does not restate exact figures as fact because the original trial publication could not be directly verified as part of this source review. Anyone citing precise response rates in a clinical or appeal letter should pull the numbers directly from the published New England Journal of Medicine trial report or the FDA label rather than from secondary summaries.

FDA's approval was granted on an accelerated pathway based on these histology and imaging endpoints, which are considered reasonably likely to predict clinical benefit but are not themselves hard outcomes like progression to cirrhosis or death. A confirmatory outcomes trial is intended to verify long-term clinical benefit; readers can check current status and expected completion on ClinicalTrials.gov by searching for resmetirom MASH outcomes studies, since specific trial identifiers were not independently confirmed for this article.

If a claim is denied

Anthem, like other insurers, is required to provide an internal appeal process and, after that is exhausted, access to an external review by a state-designated independent review organization (IRO) whose decision is binding on the plan. Typical denial reasons for a drug like this include incomplete fibrosis staging documentation, missing step-therapy records, use outside the F2-F3 label population, or a prescriber record that does not show specialist involvement. A stronger second submission usually addresses the specific reason stated in the denial letter rather than resubmitting the same packet.

A peer-to-peer conversation between the prescriber and the plan's medical director, when available, often resolves ambiguous cases faster than a written appeal alone, because the prescriber can respond to the reviewer's specific objection in real time. Appeal letters that cite the FDA label criteria and the trial's histology results (pulled from the primary publication, not a secondary summary) tend to be more persuasive than general statements about medical necessity.

Decision framework: is a Rezdiffra PA likely to succeed on Anthem?

Use this as a planning tool with your prescriber, not as a guarantee of coverage. It reflects general specialty-drug PA logic, not a confirmed Anthem policy document.

Step 1 - Confirm the label fit. Is the diagnosis MASH with biopsy- or imaging-confirmed fibrosis stage F2 or F3, without cirrhosis?

• Yes → continue to Step 2.
• No (F0/F1, or F4 cirrhosis, or simple steatosis, or a non-MASH indication) → approval is unlikely under the current FDA label; discuss alternative management with the prescriber before submitting a PA.

Step 2 - Confirm prior therapy documentation exists. Has the patient tried, or does the chart document a clear contraindication or intolerance to, a standard first-line option such as vitamin E or pioglitazone (where clinically appropriate), and lifestyle counseling?

• Yes, with dates, doses, and outcome documented → continue to Step 3.
• No, or documentation is vague ("patient reports trying diet changes") → expect a step-therapy denial; have the prescriber document specifics before submitting.

Step 3 - Confirm specialist involvement. Is the prescription written by, or does it include a note from, a gastroenterologist or hepatologist?

• Yes → continue to Step 4.
• No → contact the plan to ask whether specialist involvement is required before submitting; if it is, obtain a consult note first rather than risking a denial and restart.

Step 4 - Confirm labs and staging are recent. Are fibrosis staging results and baseline labs (including thyroid function) less than roughly a year old and attached as actual reports, not summary notes?

• Yes → submit the PA with all documents attached and confirm the correct specialty pharmacy for the specific plan before sending the prescription.
• No → order updated testing first; outdated staging is a common, avoidable reason for delay.

If denied: identify the exact reason in the denial letter, correct only that gap, request a peer-to-peer review if the objection is clinical judgment rather than missing paperwork, and file the internal appeal within the plan's stated deadline before pursuing external IRO review.

When this is not the right next step

Rezdiffra is not a substitute for urgent evaluation of decompensated liver disease. Symptoms such as jaundice, confusion, new abdominal swelling, or gastrointestinal bleeding warrant urgent medical evaluation rather than a coverage question about a chronic oral therapy. Patients with known cirrhosis or advanced liver disease should discuss the full range of monitoring and treatment options, including but not limited to resmetirom, with their hepatologist rather than assuming this drug applies to their stage of disease.